Wee1 kinase inhibitors (Acrivon Therapeutics)

N/A

Report date: 2025/03/20 09:51:43
NME

Base Information

Drug NameWee1 kinase inhibitors (Acrivon Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase WEE1 inhibitors
TargetsSerine/threonine-protein kinase WEE1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAcrivon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAcrivon Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A